Dendritic Cell Differentiation in Advanced Cancer Patients
Author Information
Author(s): H. van Cruijsen, K. Hoekman, A. G. M. Stam, A. J. M. van den Eertwegh, B. C. Kuenen, R. J. Scheper, G. Giaccone, T. D. de Gruijl
Primary Institution: VU University Medical Center
Hypothesis
Tumor-derived VEGF inhibits dendritic cell differentiation in advanced cancer patients.
Conclusion
VEGFR TK inhibition with AZD2171 does not restore defective dendritic cell differentiation in advanced cancer patients.
Supporting Evidence
- Circulating dendritic cell frequencies were significantly lower in cancer patients compared to healthy individuals.
- VEGFR TK inhibition did not significantly change the frequencies of dendritic cell precursors.
- An increased number of myeloid suppressor cells was observed in cancer patients before treatment.
Takeaway
In cancer patients, the cells that help fight tumors don't work well, and a new treatment didn't help fix them.
Methodology
The study measured dendritic cell frequencies in blood samples from advanced cancer patients before and after treatment with a VEGFR TKI.
Potential Biases
The patient population was heterogeneous, which may introduce variability in the results.
Limitations
The study's phase I design and small sample size limit the generalizability of the findings.
Participant Demographics
13 patients (3 women, 10 men) with a mean age of 52 years.
Statistical Information
P-Value
p = .002 for MDC-1, p = .001 for MDC-2, p = 0.04 for PDC
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website